Close Menu

NEW YORK — The US Food and Drug Administration on Monday issued separate Emergency Use Authorizations for SARS-CoV-2 tests developed by MiraDx, Mammoth Biosciences, and BayCare Laboratories.

The MiraDx SARS-CoV-2 RT-PCR assay is designed to detect the N gene of the virus in upper respiratory specimens such as nasal swab specimens or nasal aspirates. It uses Hamilton's Microlab STAR automated liquid handling system for nucleic acid extraction and runs on Thermo Fisher Scientific's Applied Biosystems QuantStudio 6 Flex PCR instrument.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.

Sponsored by

Management of viral infections is critical to prevent severe morbidities and consequences in immune-suppressed transplant patients.

Sponsored by
Mission Bio

Recent work by many investigators has discovered that over the course of aging, hematopoietic stem cells (HSCs) commonly undergo clonal expansion.